

Special Issue

Non-coding RNA in Hematological Cancers

Message from the Guest Editor

This Special Issue covers all types of non-coding RNAs in hematological cancers. Small RNAs consist of 17–250 nucleotides in length; among them, microRNAs (miRNAs) are the most studied and well known non-coding RNAs. Piwi-interacting RNAs (piRNAs) are the largest class of the small non-coding RNA family and are implicated in epigenetic and post-transcriptional regulation but still lack functional characterization. Long non-coding RNAs (lncRNAs) are a diverse class of RNAs, believed to play an important role in cellular mechanisms; however, little biological relevance has been established thus far. Circular RNAs (circRNAs) are a recently rediscovered RNA class of non-coding RNAs. Small nuclear/nucleolar RNAs (sn/snoRNAs) are perhaps the most ancient and highly conserved class of sncRNAs, carrying out a fundamental role in the modification and processing of ribosomal RNAs (rRNA), transfer RNAs (tRNA), and small nuclear RNAs (snRNA).

Guest Editor

Dr. Srinivas V Koduru

Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, PA 17033, USA

Deadline for manuscript submissions

closed (1 February 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/57750

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)